Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11709795 | 0.91 | KDM4E (0.52) | KDM4EMAOBSIGMAR1MAOA | |
| SCHEMBL2891337 | 0.87 | KDM4E (0.59) | KDM4EMAOBSIGMAR1MAOAMAPT | |
| SCHEMBL11720146 | 0.86 | MAOB (0.49) | KDM4EMAOBMAOA | |
| SCHEMBL5240129 | 0.84 | KDM4E (0.56) | KDM4EMAOBSIGMAR1MAOAMAPT | |
| SCHEMBL2891507 | 0.84 | CYP1A2 (0.60) | KDM4EMAOBSIGMAR1XDHTSHR | |
| SCHEMBL20982486 | 0.83 | KDM4E (0.58) | KDM4EMAOA | |
| SCHEMBL11715546 | 0.83 | NR4A1 (0.52) | KDM4EMAOBSIGMAR1MAPTCHRNA7 | |
| SCHEMBL4983089 | 0.82 | KDM4E (0.54) | KDM4EMAOBSIGMAR1MAOAMAPT | |
| SCHEMBL11709998 | 0.82 | KDM4E (0.55) | KDM4EMAOBSIGMAR1MAPTCHRNA7 | |
| SCHEMBL11655575 | 0.82 | TSHR (0.53) | KDM4EMAPTKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | TRANS TECH PHARMA, INC (US) | 2008-05-22 | — | — | US | disclosed |
| US-7329684-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7087632-B2 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2006-02-02 | — | — | US | disclosed |
| EP-1387680-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TransTech Pharma Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | TRANSTECH PHARMA, LLC | 2003-02-13 | — | — | US | disclosed |
| WO-2002069965-A1 | BENZIMIDAZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119534-A1 | Benzimidazole Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAOB 1721/4885SIGMAR1 2694/4885 |
| US-20030032663-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3282/4885MAOB 1747/4885SIGMAR1 2866/4885 |
| US-20060025464-A1 | Benzimidazole derivatives as therapeutic agents | AGER, S100B, S100A4 | KDM4E 3269/4885MAOB 1721/4885SIGMAR1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.